This is already possible, thanks to the work of researchers from Vanderbilt University (USA), who have identified a biomarker (the 2-AAA) independent of glycemia and excess weight. For 12 years they have followed a group of people and have shown that those with the highest 2-AAA concentrations have up to four times the risk of developing diabetes. A test for rapid detection is already under study.
These and other innovations are now possible in Pharmamedic.
